Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B

Launched by TAICHUNG VETERANS GENERAL HOSPITAL · Apr 30, 2019

Keywords

ClinConnect Summary

This clinical trial is comparing two medications, tenofovir alafenamide (TAF) and entecavir (ETV), to see which one works better and is safer for the kidneys in treating chronic hepatitis B. Chronic hepatitis B is a long-lasting infection that affects the liver. The trial is currently looking for participants who are over 20 years old and need antiviral treatment for their hepatitis B. However, people with serious liver or kidney issues, recent treatments for hepatitis B, or certain other health conditions cannot join the study.

If you or a loved one qualifies and decides to participate, you will be closely monitored throughout the trial to see how well the medications work for you and to check for any side effects. This study aims to provide valuable information about the best treatment options for chronic hepatitis B, helping to improve care for patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients more than 20 years old
• • 2. Chronic hepatitis B patients
• • 3. Patients who were indicated for hepatitis B virus antiviral therapy
• Exclusion Criteria:
• • 1. Decompensated liver disease (Child-Pugh B \&C)
• • 2. End stage renal disease (eGRF \< 15 ml/min/1.73m2)
• • 3. Prior use of nucleot(s)ide analogues for chronic hepatitis B
• • 4. Prior use of interferon for chronic hepatitis B within six months
• • 5. Known history of human immunodeficiency virus or hepatitis C virus co-infection
• • 6. Concurrent other uncontrolled malignancy
• • 7. Women in pregnancy or lactation
• • 8. Cannot conform to the study protocol of this study